So far, multiple humanised monoclonal antibodies and tyrosine kinase inhibitors, such as trastuzumab, pertuzumab and lapatinib, have been widely applied for the clinical treatment of HER2+ BC patients [59]. Here, ERBB2 is linked to breast cancer.